{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:40Z","timestamp":1792783360142,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Foundation for the Development of the Community"},{"name":"JSPS KAKENHI","award":["24K10538"],"award-info":[{"award-number":["24K10538"]}]},{"name":"programs for Progress of the next Cross-ministerial Strategic Innovation Promotion Program (SIP) on \u201cIntegrated Health System\u201d","award":["JPJ012425"],"award-info":[{"award-number":["JPJ012425"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13300-024-01613-7","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T02:02:40Z","timestamp":1719972160000},"page":"1821-1830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Risk of Urogenital Bacterial Infection with Sodium-Glucose Cotransporter-2 Inhibitors: A Retrospective Cohort Study Using a Claims Database"],"prefix":"10.1007","volume":"15","author":[{"given":"Takanori","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Yamana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2684-1695","authenticated-orcid":false,"given":"Shuji","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"1613_CR1","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","volume":"61","author":"T Rieg","year":"2018","unstructured":"Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61:2079\u201386.","journal-title":"Diabetologia"},{"key":"1613_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1613_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1613_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1613_CR5","first-page":"CD013650","volume":"10","author":"T Kanie","year":"2021","unstructured":"Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;10:CD013650.","journal-title":"Cochrane Database Syst Rev."},{"key":"1613_CR6","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"American Diabetes Association","year":"2022","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S125\u201343.","journal-title":"Diabetes Care"},{"key":"1613_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","volume":"21","author":"AD Kaze","year":"2022","unstructured":"Kaze AD, Zhuo M, Kim SC, et al. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol. 2022;21:47.","journal-title":"Cardiovasc Diabetol"},{"key":"1613_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s13300-021-01004-2","volume":"12","author":"TM Caparrotta","year":"2021","unstructured":"Caparrotta TM, Greenhalgh AM, Osinski K, et al. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies. Diabetes Ther. 2021;12:991\u20131028.","journal-title":"Diabetes Ther"},{"key":"1613_CR9","unstructured":"U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings About too much Acid in the Blood and Serious Urinary Tract Infections. 4 December 2015. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm. (accessed December 27, 2023)"},{"key":"1613_CR10","unstructured":"U.S. Food and Drug Administration (FDA). Safety Announcement: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. 29 Aug 2018. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm617360.htm. (accessed 16 Jan 2013)"},{"key":"1613_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s13300-020-00771-8","volume":"11","author":"T Wang","year":"2020","unstructured":"Wang T, Patel SM, Hickman A, et al. SGLT2 inhibitors and the risk of hospitalization for Fournier's gangrene: a nested case-control study. Diabetes Ther. 2020;11:711\u201323.","journal-title":"Diabetes Ther"},{"key":"1613_CR12","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1001\/jamainternmed.2019.2813","volume":"179","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Patorno E. Association of sodium-glucose cotransporter 2 inhibitor treatment with risk of hospitalization for Fournier gangrene among men. JAMA Intern Med. 2019;179:1587\u201390.","journal-title":"JAMA Intern Med"},{"key":"1613_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/dom.13886","volume":"22","author":"N Petruski-Ivleva","year":"2020","unstructured":"Petruski-Ivleva N, Schneeweiss S, Eapen S, et al. Fournier\u2019s gangrene in patients with type 2 diabetes using second-line antidiabetic medications. Diabetes Obes Metab. 2020;22:267\u201371.","journal-title":"Diabetes Obes Metab"},{"key":"1613_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000985","volume":"8","author":"JY Yang","year":"2020","unstructured":"Yang JY, Wang T, Pate V, et al. Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier\u2019s gangrene. BMJ Open Diabetes Res Care. 2020;8: e000985.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1613_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40801-021-00266-3","volume":"8","author":"K Hiramatsu","year":"2021","unstructured":"Hiramatsu K, Barrett A, Miyata Y, PhRMA Japan Medical Affairs Committee Working Group 1. Current status, challenges, and future perspectives of real-world data and real-world evidence in Japan. Drugs Real World Outcomes. 2021;8:459\u201380.","journal-title":"Drugs Real World Outcomes."},{"key":"1613_CR16","unstructured":"JMDC Inc. JMDC Claims Database. https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database. (accessed 16 Jan 2023)"},{"key":"1613_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Kim D, et al. Sodium-glucose cotransporter\u20132 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171:248\u201356.","journal-title":"Ann Intern Med"},{"key":"1613_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110200","volume":"195","author":"GC Chan","year":"2023","unstructured":"Chan GC, Ng JK, Chow KM, et al. SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: a population-based propensity score-matched cohort study. Diabetes Res Clin Pract. 2023;195: 110200.","journal-title":"Diabetes Res Clin Pract"},{"key":"1613_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1099\/00222615-48-6-535","volume":"48","author":"SE Geerlings","year":"1999","unstructured":"Geerlings SE, Brouwer EC, Gaastra W, et al. Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol. 1999;48:535\u20139.","journal-title":"J Med Microbiol"},{"key":"1613_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12933-017-0654-z","volume":"17","author":"MV Karg","year":"2018","unstructured":"Karg MV, Bosch A, Kannenkeril D, et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol. 2018;17:5.","journal-title":"Cardiovasc Diabetol"},{"key":"1613_CR21","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/dom.15091","volume":"25","author":"A Kang","year":"2023","unstructured":"Kang A, Smyth B, Neuen BL, et al. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: a pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023;25:2151\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"1613_CR22","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/dom.13184","volume":"20","author":"E Patorno","year":"2018","unstructured":"Patorno E, Gopalakrishnan C, Franklin JM, et al. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes Obes Metab. 2018;20:974\u201384.","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01613-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-024-01613-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01613-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T14:17:36Z","timestamp":1721657856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-024-01613-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1613"],"URL":"https:\/\/doi.org\/10.1007\/s13300-024-01613-7","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takanori Imai, Naoto Kato, Naoki Kanda, Hideki Hashimoto, Hayato Yamana, and Shuji Hatakeyama declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Ethics Committee of Jichi Medical University has approved this study and waived the requirement for informed consent owing to the retrospective design and use of anonymized data (approval number, 21\u2013198). This study was performed in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}